REPCF (0913693 BC) Cyclically Adjusted PB Ratio: (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


0913693 BC  (OTCPK:REPCF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


0913693 BC Cyclically Adjusted PB Ratio Related Terms


0913693 BC Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Cyclically Adjusted PB Ratio Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 11.13 2.93 9.11 18.36

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.08 18.36 42.32 32.70 0.00

REPCF vs VRTX, REGN, SGEN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, 0913693 BC's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


0913693 BC Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Cyclically Adjusted PB Ratio falls into.



0913693 BC Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

0913693 BC's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, 0913693 BC's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.075/125.2304*125.2304
=-0.075

Current CPI (Sep. 2023) = 125.2304.

0913693 BC Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.288 96.945 0.372
201403 0.178 98.604 0.226
201406 0.689 99.473 0.867
201409 0.504 99.394 0.635
201412 0.285 98.367 0.363
201503 0.096 99.789 0.120
201506 0.166 100.500 0.207
201509 0.011 100.421 0.014
201512 -0.069 99.947 -0.086
201603 -0.109 101.054 -0.135
201606 -0.145 102.002 -0.178
201609 -0.205 101.765 -0.252
201612 0.058 101.449 0.072
201703 0.114 102.634 0.139
201706 0.015 103.029 0.018
201709 -0.036 103.345 -0.044
201712 -0.012 103.345 -0.015
201803 -0.029 105.004 -0.035
201806 -0.050 105.557 -0.059
201809 -0.067 105.636 -0.079
201812 -0.053 105.399 -0.063
201903 -0.028 106.979 -0.033
201906 -0.053 107.690 -0.062
201909 -0.069 107.611 -0.080
201912 -0.119 107.769 -0.138
202003 -0.083 107.927 -0.096
202006 -0.089 108.401 -0.103
202009 -0.086 108.164 -0.100
202012 -0.118 108.559 -0.136
202103 -0.128 110.298 -0.145
202106 -0.129 111.720 -0.145
202109 -0.135 112.905 -0.150
202112 -0.153 113.774 -0.168
202203 -0.150 117.646 -0.160
202206 -0.141 120.806 -0.146
202209 -0.154 120.648 -0.160
202212 -0.091 120.964 -0.094
202303 -0.061 122.702 -0.062
202306 -0.070 124.203 -0.071
202309 -0.075 125.230 -0.075

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.